Atria's Q3 results were in line with LSEG Data & Analytics consensus expectations. The African Swine Fever outbreak in Finland had around a EUR 2m negative impact in Q3, while Atria Sweden improved its profitability significantly. The company is clearly gaining traction in Sweden and expanding its product offering. Atria reiterated its guidance which we view reachable with the improved performance in Sweden. We leave our DCF- and multiples-based fair value range of EUR 18.4-22.5 intact.
LÄS MER
